Eurobio Scientific launches its COVID antigen self-test
03 Giugno 2021 - 4:01PM
Eurobio Scientific launches its COVID antigen self-test
Eurobio Scientific
launches its COVID antigen self-test
Paris, June
2, 2021 –
5:45
pm
Eurobio
Scientific (FR0013240934, ALERS, PEA-PME
eligible), a leading French group in specialty in vitro medical
diagnostics, announces the launch of its new proprietary test EBS
1005, an antigen self-test developed to identify the presence of
the SARS-CoV-2 coronavirus by simple nasal sampling.
An easy to use
proprietary antigen self-test
The proprietary EBS 1005 test received today an
exemption from the French health authority, ANSM, to be marketed
until CE marking is obtained. It also received a similar waiver
from German health authorities. The test is intended to be sold in
boxes of 5 tests, directly by pharmacies or under government
contracts.
EBS 1005 includes 5 unit test kits, each
including an instructions leaflet, a nasal swab to be inserted for
only 2 to 3 centimeters into the nose, a ready-to-use reagent, and
the test plate. Very easy to use with a minimally invasive
sampling, the test gives a result in 10 minutes, with excellent
performance (specificity> 99%, sensitivity> 93%).
This test complements Eurobio Scientific's COVID
diagnostics offering, which includes:
- PCR tests including the proprietary
EBX range with, among others, a test for the detection and
qualification of SARS-CoV-2 variants (EBX 046),
- automated serological tests,
and
- another proprietary antigen test
for healthcare professionals, EBS 1020.
Marketed in several European countries, EBS 1005
helps support government strategies for managing the COVID-19
pandemic in parallel with vaccination campaigns.
|
About Eurobio
ScientificEurobio Scientific is a key player in the field
of specialty in vitro diagnostics. It is involved from research to
manufacturing and commercialization of diagnostic tests in the
fields of transplantation, immunology and infectious diseases, and
sells instruments and products for research laboratories, including
biotechnology and pharmaceutical companies. Through many
partnerships and a strong presence in hospitals, Eurobio Scientific
has established its own distribution network and a portfolio of
proprietary products in the molecular biology field. The Group has
approximately 148 employees and three production units based in the
Paris region, in Germany and in the United States, and several
affiliates based in Dorking UK, Sissach Switzerland, Bünde Germany
and Utrecht in The Netherlands. For more information, please visit
: www.eurobio-scientific.com The company is publicly listed on the
Euronext Growth market in ParisEuronext Growth BPI Innovation,
PEA-PME 150 and Next Biotech indices, Euronext European Rising Tech
label.Symbol: ALERS - ISIN Code: FR0013240934 - Reuters: ALERS.PA -
Bloomberg: ALERS:FP |
|
Contacts |
|
Group Eurobio ScientificDenis Fortier, General
ManagerHervé Duchesne de Lamotte, General ManagerTel. +33(0) 1 69
79 64 80 |
CalyptusMathieu Calleux / Gregory BossonInvestors
relationsTel. +33(1) 53 65 68 68
eurobio-scientific@calyptus.net |
Grafico Azioni Eurobio Scientific (EU:ALERS)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Eurobio Scientific (EU:ALERS)
Storico
Da Apr 2023 a Apr 2024
